Skip to content
Awesome – Lifestyle
Author:
Damora Therapeutics, Inc.
Damora Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
November 4, 2026
Damora Therapeutics to Present New Preclinical Data Highlighting Potentially Best-in-Class Pan-Mutant Activity of DMR-001 in Mutant Calreticulin (mutCALR)-driven Myeloproliferative Neoplasms (MPN) at the American Society of Hematology (ASH) 2026 Annual Meeting
November 4, 2026
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 3, 2026
Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
August 10, 2026
Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis
August 5, 2026
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 3, 2026
Damora Announces Redomestication from Delaware to Cayman Islands
July 17, 2026
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 1, 2026
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 1, 2026
1
2
Next Page
→